Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers

Steven A. Taylor, Grace A. Lee, Vivian Y. Pao, Jayaranjan Anthonypillai, Francesca T. Aweeka, Jean Marc Schwarz, Kathleen Mulligan, Morris Schambelan, Carl Grunfeld

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background: Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection and changes in body composition. Boosting dose ritonavir (100-200 mg) is the most commonly prescribed PI, yet its effects on glucose metabolism have not been described in the absence of another PI. Methods: In this randomized, double-blind, cross-over study, a single dose of ritonavir 200 mg or placebo was given to healthy HIV-seronegative volunteers before assessment of insulin sensitivity by euglycemic hyperinsulinemic clamp. Results: Boosting dose ritonavir had no effect on insulin-mediated glucose disposal (M/I, placebo: 8.59 ± 0.83 vs. ritonavir: 8.51 ± 0.64 mg/kg per minute per μU/mL insulin, P = 0.89). Conclusions: A single boosting dose of ritonavir does not alter insulin sensitivity, suggesting lopinavir is likely responsible for the induction of insulin resistance demonstrated in prior short-term studies of lopinavir/ritonavir. There is a dose-dependent effect of ritonavir on insulin sensitivity.

Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume55
Issue number3
DOIs
StatePublished - Nov 1 2010

Fingerprint

Ritonavir
Insulin Resistance
Volunteers
HIV
Lopinavir
Protease Inhibitors
Placebos
Insulin
HIV Protease Inhibitors
Glucose
Glucose Clamp Technique
Body Composition
Cross-Over Studies
HIV Infections

Keywords

  • glucose
  • HIV protease inhibitors
  • insulin resistance
  • lopinavir
  • ritonavir

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Taylor, S. A., Lee, G. A., Pao, V. Y., Anthonypillai, J., Aweeka, F. T., Schwarz, J. M., ... Grunfeld, C. (2010). Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. Journal of Acquired Immune Deficiency Syndromes, 55(3), 361-364. https://doi.org/10.1097/QAI.0b013e3181e6a7d9

Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. / Taylor, Steven A.; Lee, Grace A.; Pao, Vivian Y.; Anthonypillai, Jayaranjan; Aweeka, Francesca T.; Schwarz, Jean Marc; Mulligan, Kathleen; Schambelan, Morris; Grunfeld, Carl.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 55, No. 3, 01.11.2010, p. 361-364.

Research output: Contribution to journalArticle

Taylor, SA, Lee, GA, Pao, VY, Anthonypillai, J, Aweeka, FT, Schwarz, JM, Mulligan, K, Schambelan, M & Grunfeld, C 2010, 'Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers', Journal of Acquired Immune Deficiency Syndromes, vol. 55, no. 3, pp. 361-364. https://doi.org/10.1097/QAI.0b013e3181e6a7d9
Taylor, Steven A. ; Lee, Grace A. ; Pao, Vivian Y. ; Anthonypillai, Jayaranjan ; Aweeka, Francesca T. ; Schwarz, Jean Marc ; Mulligan, Kathleen ; Schambelan, Morris ; Grunfeld, Carl. / Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. In: Journal of Acquired Immune Deficiency Syndromes. 2010 ; Vol. 55, No. 3. pp. 361-364.
@article{08bba069b51a4bc9a02d598d5b74fb12,
title = "Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers",
abstract = "Background: Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection and changes in body composition. Boosting dose ritonavir (100-200 mg) is the most commonly prescribed PI, yet its effects on glucose metabolism have not been described in the absence of another PI. Methods: In this randomized, double-blind, cross-over study, a single dose of ritonavir 200 mg or placebo was given to healthy HIV-seronegative volunteers before assessment of insulin sensitivity by euglycemic hyperinsulinemic clamp. Results: Boosting dose ritonavir had no effect on insulin-mediated glucose disposal (M/I, placebo: 8.59 ± 0.83 vs. ritonavir: 8.51 ± 0.64 mg/kg per minute per μU/mL insulin, P = 0.89). Conclusions: A single boosting dose of ritonavir does not alter insulin sensitivity, suggesting lopinavir is likely responsible for the induction of insulin resistance demonstrated in prior short-term studies of lopinavir/ritonavir. There is a dose-dependent effect of ritonavir on insulin sensitivity.",
keywords = "glucose, HIV protease inhibitors, insulin resistance, lopinavir, ritonavir",
author = "Taylor, {Steven A.} and Lee, {Grace A.} and Pao, {Vivian Y.} and Jayaranjan Anthonypillai and Aweeka, {Francesca T.} and Schwarz, {Jean Marc} and Kathleen Mulligan and Morris Schambelan and Carl Grunfeld",
year = "2010",
month = "11",
day = "1",
doi = "10.1097/QAI.0b013e3181e6a7d9",
language = "English (US)",
volume = "55",
pages = "361--364",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers

AU - Taylor, Steven A.

AU - Lee, Grace A.

AU - Pao, Vivian Y.

AU - Anthonypillai, Jayaranjan

AU - Aweeka, Francesca T.

AU - Schwarz, Jean Marc

AU - Mulligan, Kathleen

AU - Schambelan, Morris

AU - Grunfeld, Carl

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Background: Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection and changes in body composition. Boosting dose ritonavir (100-200 mg) is the most commonly prescribed PI, yet its effects on glucose metabolism have not been described in the absence of another PI. Methods: In this randomized, double-blind, cross-over study, a single dose of ritonavir 200 mg or placebo was given to healthy HIV-seronegative volunteers before assessment of insulin sensitivity by euglycemic hyperinsulinemic clamp. Results: Boosting dose ritonavir had no effect on insulin-mediated glucose disposal (M/I, placebo: 8.59 ± 0.83 vs. ritonavir: 8.51 ± 0.64 mg/kg per minute per μU/mL insulin, P = 0.89). Conclusions: A single boosting dose of ritonavir does not alter insulin sensitivity, suggesting lopinavir is likely responsible for the induction of insulin resistance demonstrated in prior short-term studies of lopinavir/ritonavir. There is a dose-dependent effect of ritonavir on insulin sensitivity.

AB - Background: Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection and changes in body composition. Boosting dose ritonavir (100-200 mg) is the most commonly prescribed PI, yet its effects on glucose metabolism have not been described in the absence of another PI. Methods: In this randomized, double-blind, cross-over study, a single dose of ritonavir 200 mg or placebo was given to healthy HIV-seronegative volunteers before assessment of insulin sensitivity by euglycemic hyperinsulinemic clamp. Results: Boosting dose ritonavir had no effect on insulin-mediated glucose disposal (M/I, placebo: 8.59 ± 0.83 vs. ritonavir: 8.51 ± 0.64 mg/kg per minute per μU/mL insulin, P = 0.89). Conclusions: A single boosting dose of ritonavir does not alter insulin sensitivity, suggesting lopinavir is likely responsible for the induction of insulin resistance demonstrated in prior short-term studies of lopinavir/ritonavir. There is a dose-dependent effect of ritonavir on insulin sensitivity.

KW - glucose

KW - HIV protease inhibitors

KW - insulin resistance

KW - lopinavir

KW - ritonavir

UR - http://www.scopus.com/inward/record.url?scp=78049317637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049317637&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3181e6a7d9

DO - 10.1097/QAI.0b013e3181e6a7d9

M3 - Article

C2 - 20595906

AN - SCOPUS:78049317637

VL - 55

SP - 361

EP - 364

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 3

ER -